Pipeline
About GB-X01
Features
-
Product origin
Single strain bacteria isolated from healthy donor
-
Safety
Safety confirmed by non clinical toxicity study
-
Production
Drug product manufacturing with Biose industrie
-
Efficacy research
Confirmed antitumor efficacy in both syngeneic and xenograft mouse models
Cancer prevention and treatment effects through inhibition of cancer cell growth and activation of immune cells
-
Clinical development
Focused on combination therapy with existing oncology products and pipelines
To develop therapeutics for solid tumors such as colorectal cancer
-
Intellectual property
Filed compound and use patent
Description
Microbiome therapeutics that elicit preventive and therapeutic anti-tumorigenic efficacy
in combination therapy with existing chemotherapy, targeted / immuno oncology and cell therapy
using syngeneic, xenograft and humanized mouse model